The pharmacokinetic behaviour and phototherapeutic effectiveness of bis(di-isobutyloctadecylsiloxy)-2,3-naphthalocyanatosilicon (iso-BOSiNc) incorporated into dipalmitoyl-phosphatidylcholine (DPPC) liposomes have been studied in Balb/c mice bearing an MS-2 fibrosarcoma. We found that iso-BOSiNc i.v. -injected at a dose of 0.5 mg kg-' b.w. is preferentially transported by serum lipoproteins; in particular, the photosensitiser is associated with LDL (57.8% of total recovery in the serum) and HDL (35.7%) while minor amounts are associated to VLDL (2.63%) and other serum proteins (3.89%), Iso-BOSiNc concentrations greater than 1 gig g-' of tissue are recovered from the tumour at 12 -48 h after administration while the ratio of iso-BOSiNc concentration in tumour and peritumoral tissue is greater than 10. Upon increasing the injected dose, the additional iso-BOSiNc is almost exclusively bound by HDL, which leads to large uptake of the photosensitiser by liver and spleen. The efficiency of iso-BOSiNc as a photodynamic agent was measured upon irradiation with a different dose-rate for a total light dose of 450 J cm-2. The extent of tumour necrotic area increases as a function of the time after the end of PDT treatment and reaches a maximum level after about 24 h. Moreover, the necrotic area is linearly dependent on the irradiation dose-rate up to 100 mW cm-2. In all there is substantial evidence that iso-BOSiNc delivered in a liposomal dispersion is a highly effective photosensitizer for PDT of tumours.
Photodynamic therapy (PDT) is a method of cancer treatment, based on photosensitisation of the tumour to selected wavelengths of visible light by phototherapeutic agents (Wilson & Jeeves, 1987) . At present PDT is applied at the clinical level using haematoporphyrin-IX (Hp-IX) and haematoporphyrin derivative (HpD) (Dougherty, 1987) as photodynamic agents. However, Hp and HpD show a small efficiency of red light absorption; moreover, HpD is a highly heterogeneous mixture of porphyrins, while the clinically used Hp contains about 15% porphyrin-type impurities (Jori et al., 1983) .
Other classes of photosensitisers, such as phthalocyanines and chlorins, are provided with better red light-absorbing properties than Hp: their absorption maxima are located around 670 nm with extinction coefficients about 105 M-l cm-'; moreover, they are usually characterised by a good degree of purity (Zhou, 1989) . Recently, naphthalocyanines have been proposed as PDT agents (Firey & Rodgers, 1987) , since these compounds show intense absorption (a> IO M-l cm-') around 780 nm, namely in a spectral interval where light penetration through the skin is approximately twice that at 630 nm (Wilson & Jeeves, 1987) .
In this work we have studied the pharmacokinetic and phototherapeutic properties of bis(di-isobutyloctadecylsiloxy) -2,3-naphthalocyanato silicon (iso-BOSiNc) in mice bearing a transplanted tumour. Flash photolysis studies (Firey & Rodgers, 1987; Ford et al., 1988) have shown that isoBOSiNc triplet state has a long natural lifetime (331 jis) and is produced with a quantum yield of 0.2. In oxygen-saturated solutions of iso-BOSiNc in benzene the quantum yield of singlet oxygen generation is 0.2; it is likely that this activated derivative of oxygen plays a major role in photoinduced necrosis of tumours (Moan, 1986) .
Materials and methods

Chemicals
Bis(di-isobutyloctadecylsiloxy)-2,3-naphthalocyanato silicon (iso-BOSiNc) was prepared at >99% purity by a procedure similar to that described for the bis(tri-n-hexylsiloxy) derivative (Wheeler et al., 1984) . The suspension was sonicated for 30 min at 50°C, allowed to spontaneously cool to room temperature and centrifuged at 3,500-4,000 r.p.m. for 10 min. The surnatant contains small unilamellar DPPC liposomes with an external diameter of about 28 nm, as assessed by electron microscopy. IsoBOSiNc is incorporated into the liposomal vesicles in a monomeric form as suggested by the position of the absorption maximum at 774 nm and the presence of fine structure in the red absorption region (Figure 1 ). The absorption spectrum is coincident with the fluorescence excitation spectrum (emission wavelength, 780 nm), in agreement with the fact that aggregated naphthalocyanines have a very low, if any, fluorescence quantum yeld. The iso-BOSiNc concentration in the liposome suspension was calculated by absorbance at 774 nm using e = 5.57 x 105 M-l cm' in tetrahydrofuran (W.E. Ford, personal communication) .
Pharmacokinetic studies Thirty tumour-bearing mice were intravenously injected with two different doses (2 mg kg-' and 0.5 mg kg-') of isoBOSiNc incorporated into DPPC liposomes. The mice (three mice at each time) were killed at 3 h, 12 h, 24 h, 48 h and 1 week after injection and the serum, the tumour and selected normal tissues (liver, spleen, skin, brain, lung, kidneys and muscle in the contralateral leg) were quickly removed and washed with saline. The same tissues were also analysed in uninjected mice.
It was not possible to follow the pharmacokinetic behaviour of iso-BOSiNc at times longer than 1 week after injection since the MS-2 fibrosarcoma shows a substantial amount of spontaneous necrosis after about 20 days from transplantation. However, we have followed the pharmacokinetic behaviour of iso-BOSiNc in selected tissues of healthy mice at times between 1 and 4 weeks after injection.
In order to extract iso-BOSiNc, about 200mg of tissue were thoroughly homogenised with a Teflon homogeniser in a Potter vessel using 2 ml of 2% aqueous SDS. The homogenate was then diluted with 2 ml of 2% aqueous SDS and incubated for I h at room temperature under gentle magnetic stirring. The suspension thus obtained was centrifuged at 3,000 r.p.m. at room temperature for 15 min. A portion of the surnatant (1 ml) was added to 2 ml of tetrahydrofuran. The resulting mixture was centrifuged at 3,000 r.p.m. for 15 min, the surnatant was collected and analysed by a spectrophotofluorimetric procedure as specified below. In preliminary experiments, we observed that a second treatment of the pellet by the same extraction procedure gave iso-BOSiNc recoveries which were always lower than 5% of the originally extracted amount.
The serum was isolated from blood by centrifugation at 3,000 r.p.m. for 15 min. Fifty microlitres of the serum was added to 700 pl of 2% aqueous SDS and 1.5 ml of tetrahydrofuran, and the mixture was centrifuged at 3,000 r.p.m. for 15 min after which the surnatant was collected and analysed. The fluorescence spectrum of the solutions was recorded at Chromatographic studies Chromatographic analyses of sera taken at 2 h after administration of iso-BOSiNc were obtained from mice injected with two doses of photosensitiser (0.5 and 2.0 mg kg-'). The serum was taken 2 h after administration of iso-BOSiNc. Serum samples were chromatographed on a column (1.7 x 140 cm) of Sephacryl S-300, which had been equilibrated with 0.01 M phosphate buffer at pH 7.4, containing 0.15 M NaCl. The column was eluted at a flow rate of 31.2 ml h-' and 2.6 ml fractions were collected. The fraction collector was connected to a 2238 LKB UV-cord and the protein content was continuously recorded by monitoring the absorbence of the eluate at 280 nm. The collected fractions were also assayed for 780 nm fluorescence emission exciting at 690 nm.
Discontinuous density gradient ultracentrifugation of sera Ultracentrifuge analysis of the distribution of iso-BOSiNc among the various lipoprotein classes were obtained from serum of healthy rabbits injected with 0.5 and 1.0 mg kg-' iso-BOSiNc. The distribution of dyes in rabbit serum is essentially identical to that observed in mouse serum (Jori, 1985) . The serum (15 ml) was taken at 2 h after administration.
Ultracentrifugation studies were performed at 39,000 The purity of the fractions was assayed by agarose gelelectrophoresis. The content of proteins, triglycerides, phospholipids and cholesterol was measured in order to calculate the total lipoprotein mass (holoprotein) (Barel et al., 1986) .
The amount of iso-BOSiNc bound with each protein fraction was determined by spectrophotofluorimetric analysis after extraction of the photosensitiser.
Photodynamic therapy
For experimental PDT studies we have used tumour-bearing mice injected with 0.5 mg kg-' lipsome-bound iso-BOSiNc. Phototreatments were performed at 24 h after administration of the drug. Light from a 250 W halogen lamp (Teclas, Lugano, Switzerland) was focused into a bundle of optical fibres having a total diameter of 0.6 cm. The fibre tip was placed at 1 cm from the surface of the tumour. The lamp was equipped with a set of optical cut-on and cut-off filters which eliminated all visible and infrared radiation outside the 700-800 nm interval. The development of tumour necrotic area was measured as a function of time after the end of PDT. In general the tumour was irradiated at a dose-rate of 180 mW cm-2 (measured at the end of the fibre bundle) and a total light dose of 450 J cm-2. The extent of tumour necrotic area was also measured as a function of the irradiation dose-rate in order to define the optimal phototherapeutic parameters. In this case the tumour was irradiated at a total light dose of 450 J cm-2 and the necrotic area was analysed at 24 h after the end of PDT. The procedure for measuring the extent of tumour necrosis involved the fixation of the tumour in 10% formalin, followed by sectioning the tumour at 2 mm intervals. The width and depth of the necrotic area were measured for each tissue slice. The maximum values of width and depth were recorded for each tumour and their product was used as a quantitative evaluation of the tumour response . Each point reported in Figures  4 and 5 represents the mean ( ± s.d.) from three animals.
Results
Pharmacokinetic studies
The recovery of iso-BOSiNc from tumour, serum and selected normal tissues at different times after injection of 2 mg kg-' is reported in Table I . The data represent the average of recoveries from at least three different mice, the largest devia-tion from the reported values being 15%. The clearance of the drug from the serum follows biphasic kinetics; about 90% of photosensitiser is eliminated during the initial 24 h. Significant concentrations of photosensitiser, of the order of gsg per g of tissue, are accumulated and retained by the tumour. On the other hand, the peritumoral tissue (i.e. muscle) accumulates significantly smaller amounts of isoBOSiNc and the ratio of iso-BOSiNc concentration in tumour and muscle ranges between 10 and 20. Unusually large amounts of iso-BOSiNc are recovered in the liver and spleen and they are present even at I week after administration. Pharmacokinetic studies with normal mice show that large concentrations of iso-BOSiNc are recovered from liver and spleen also at 4 weeks after injection of 2 mg kg-' (Table   III) . Moreover, the iso-BOSiNc concentration in the skin shows a tendency to increase at long times after injection.
This fact may be related with the prolonged retention of liposome-associated drugs by serum high-density lipoproteins , which could release iso-BOSiNc to cutaneous districts.
At a lower injected dose of photosensitiser (0.5 mg kg-') we find again a high ratio of iso-BOSiNc concentration in the tumour and muscle (Table II) . However, the amounts of drug taken up by the liver and spleen is substantially reduced and a gradual elimination of iso-BOSiNc from these tissues can be observed. Similar pharmacokinetic data are obtained for normal mice injected with 0.5 mg kg-': as shown in Table  III the photosensitiser is slowly eliminated from the liver while there are similar concentrations of iso-BOSiNc in the spleen at times between 1 and 4 weeks after injection. molecular weight class of proteins, the peak 'B' represents the lipoproteins and the peak 'C' represents mainly albumin and globulins (Barel et al., 1986) . Clearly, the dye is distributed among all serum proteins, although the fraction associated with peak 'A' is substantially reduced upon injection of 0.5 mg kg-'. In all cases, the absorption and fluorescence properties of iso-BOSiNc in the different fractions were typical of the monomeric dye.
The results of ultracentrifuge analysis of the distribution of iso-BOSiNc among the various lipoprotein classes are shown in Table IV. Phototherapy studies Our PDT protocol causes the appearance of tumour necrosis within about 12 h from the end of phototreatment. On the other hand, no appreciable photodamage (e.g. oedema, erythema or ulceration) is observed in the skin overlying or adjacent to the tumour. Figure 4 shows the extent of tumour necrotic area as a function of time after the end of PDT. The necrotic area reaches a maximum level (total necrosis) at about 24 h after the end of PDT. In Figure 5 we show the extent of tumour necrosis as a function of the irradiation dose rate. Apparently, tumour necrosis increases with increasing dose-rate; in particular, the necrotic area and dose rate (in the range between 100 mW cm-2 and 180 mW cm-2) seem to be linearly correlated. Effect of irradiation dose-rate on the extent of the necrotic area obtained by PDT (Zhou, 1989) . As a consequence, iso-BOSiNc should not induce toxic effects at the level of the central nervous system. The very small amounts of drug accumulated by kidneys suggest that iso-BOSiNc (as other photosensitisers) is mostly eliminated from the organism via the bile-gut pathway (Reddi et al., 1987) . Actually, large amounts of the drug are present in the liver and in the spleen even at one week after administration of 2mgkg-1 iso-BOSiNc. The prolonged retention of this photosensitiser by the main components of the reticuloendothelial system is further confirmed by our pharmacokinetic studies with normal mice. On the other hand, we observe a faster kinetics of iso-BOSiNc elimination by the liver and the spleen after injection of a lower dose (0.5mgkg-').
This . PDT experiments show that the irradiation of tumour at 24 h after injection of 0.5 mg kg-' iso-BOSiNc induces an extensive necrosis which reaches a maximum level (total necrosis) at about 24 h after the end of the phototreatment, when dose-rates as large as 180 mW cm2 are used. In this connection, the phototherapeutic efficiency of iso-BOSiNc is comparable with that observed upon injection of the same tumour model with 0.2 mg kg-' Zinc(II)-phthalocyanine or 10 mg kg-' Hp (Cozzani et al., 1984; Reddi et al., 1990) . The observed increase of the photodamaged tumour area upon increasing the dose-rate probably does not reflect a significant contribution from thermal damage. Actually irradiation of tumour tissues in uninjected mice at 180 mW cm-2 caused no detectable damage. Under these experimental conditions, the increase of tissue temperature above the basal level (29-30°C) for the anaesthetised mice was not greater than 5°C, which is lower than that usually considered to originate hyperthermal effects (Evensen & Moan, 1988 ). Henderson and Mayhew (1990) observed a good response of subcutaneously implanted RIF (radiation induced fibrosarcoma) in iso-BOSiNc treated mice to light doses (135 J cm2, 75-100 mW cm-2) lower than those used in the present I study. This can be explained by several differences existing between the two experimental protocols: the tumour type and location (intramuscolar vs subcutaneous) often cause different levels of photosensitivity; moreover, the liposomal carriers of iso-BOSiNc were different, which may result in different modalities of photosensitiser transport in the serum and different distribution of the photosensitiser among the tissular compartments (Ginevra et al., 1990) . Actually, Henderson and Mayhew (1990) found a large extent of PDT-induced vascular damage in their tumour animal model, while ultrastructural studies on tissue specimens taken from the irradiated MS-2 fibrosarcoma demonstrate a highly preferential direct damage of malignant cells (Jori & Cuomo, unpublished observations) .
